Skip to main content

Table 1 Patient characteristics according to absolute lymphocyte count

From: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

 

High ALC

(N= 82)

Low ALC

(N= 36)

P-value

Age

   

   < 60 vs. ≥ 60 years

51/31

21/15

0.692

Gender

   

   Male vs. Female

55/27

24/12

0.966

Performance status

   

   0-1 vs. 2-4

74/8

30/6

0.355

B symptom

   

   Present vs. Absent

21/61

11/25

0.578

Stage

   

   1-2 vs. 3-4

31/51

8/28

0.098

Extranodal involvement

   

   0-1 vs. ≥ 2

62/20

21/15

0.059

Bone marrow involvement

   

   Positive vs. Negative

21/61

12/24

0.389

LDH

   

   Normal vs. Elevated

45/37

12/24

0.031

IPI

   

   L, LI vs. HI, H

57/25

18/18

0.043

PIT

   

   Group 1-2 vs. 3-4

57/25

16/20

0.010

CR

   

   CR vs. non-CR

42/37

14/12

0.952

Response (≥ PR)

   

   Responder vs. Non-responder

61/18

17/9

0.231

TRM during the 1st line chemotherapy

   

   Yes vs. No

4/78

9/27

0.003

Cycles of 1st line Chemotherapy

   

   Median, range

6 (1-8)

3 (1-9)

0.007

  1. LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; CR, complete response; PR, partial response; TRM, treatment related mortality; ALC, absolute lymphocyte count.